Clinical trial · Interventional
Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer
NCT01477866CI-TRIAL-00030782CITOGENEX PAsuspendedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): the study has never started
Summary
Brief summary (as posted)
The main aim of the present study is to test the efficacy and safety of CITOGENEX administration in patients with colon-rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| citogenex | Dietary Supplement | — | UNRESOLVED |
| conventional therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- citogenex
- description
- citogenex + conventional therapy
- interventionNames
- Dietary Supplement: citogenex
- Other: conventional therapy
- type
- ACTIVE_COMPARATOR
- label
- conventional therapy
- description
- conventional therapy
- interventionNames
- Other: conventional therapy
Primary outcomes (1)
- measure
- All cause mortality
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * stage IIIa-IIIc (AJCC/TNM)
References
Publications (0)
Data not yet available
No reference posted for this study.